RT Journal Article
T1 Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease Severity.
A1 Guijarro, Luis G
A1 Cano-Martinez, David
A1 Toledo-Lobo, M Val
A1 Ruiz-Llorente, Lidia
A1 Chaparro, Maria
A1 Guerra, Ivan
A1 Iborra, Marisa
A1 Cabriada, Jose Luis
A1 Bujanda, Luis
A1 Taxonera, Carlos
A1 Garcia-Sanchez, Valle
A1 Marin-Jimenez, Ignacio
A1 Barreiro-de Acosta, Manuel
A1 Vera, Isabel
A1 Martin-Arranz, Maria Dolores
A1 Mesonero, Francisco
A1 Sempere, Laura
A1 Gomollon, Fernando
A1 Hinojosa, Joaquin
A1 Zoullas, Sofia
A1 Monserrat, Jorge
A1 Menor-Salvan, Cesar
A1 Alvarez-Mon, Melchor
A1 Gisbert, Javier P
A1 Ortega, Miguel A
A1 Hernandez-Breijo, Borja
K1 AIF-1
K1 CRP
K1 Crohn’s disease
K1 Anti-TNFs
AB Recently, increased tissue levels of AIF-1 have been shown in experimental colitis, supporting its role in intestinal inflammation. Therefore, we studied the levels of AIF-1 in Crohn’s disease (CD). Methods: This study included 33 patients with CD (14 men and 19 women) who participated in the PREDICROHN project, a prospective multicenter study of the Spanish Group of Inflammatory bowel disease (GETECCU). Results: This article demonstrates declines with respect to baseline levels of serum AIF-1 in Crohn’s disease (CD) patients after 14 weeks of treatment with anti-TNFs. Furthermore, in patients with active CD (HB ≥ 5), serum AIF-1 levels were significantly higher than those in patients without activity (HB ≤ 4). The study of serum AIF-1 in the same cohort, revealed an area under the ROC curve (AUC) value of AUC = 0.66 (p = 0.014), while for the CRP (C-reactive protein), (AUC) value of 0.69 (p = 0.0066), indicating a similar ability to classify CD patients by their severity. However, the combination of data on serum levels of AIF-1 and CRP improves the predictive ability of these analyses for classifying CD patients as active (HB ≥ 5) or inactive (HB ≤ 4). When we used the odds ratio (OR) formula, we observed that patients with CRP > 5 mg/L or AIF-1 > 200 pg/mL or both conditions were 13 times more likely to show HB ≥ 5 (active CD) than were those with both markers below these thresholds. Conclusion: The development of an algorithm that includes serum levels of AIF-1 and CRP could be useful for assessing Crohn’s disease severity.
PB MDPI
SN 2227-9059
YR 2022
FD 2022-03-21
LK http://hdl.handle.net/10668/20825
UL http://hdl.handle.net/10668/20825
LA en
NO Guijarro LG, Cano-Martínez D, Toledo-Lobo MV, Ruiz-Llorente L, Chaparro M, Guerra I, et al. Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease Severity. Biomedicines. 2022 Mar 21;10(3):727
DS RISalud
RD Sep 14, 2025